Execution of License Agreement on Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory
November 5, 2009
KYORIN Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Chiyoda-ku, Tokyo, President: Keiji Hirai, Ph.D.), a wholly owned subsidiary of KYORIN Co., Ltd., today entered into a License Agreement for Neramexane, a tinnitus treatment product currently being developed in the US and Europe, with Merz Pharmaceuticals GmbH ("Merz") (Head office: Frankfurt am Main, Germany, CEO: Martin Zügel, Ph.D.) for the territory of Japan.
- Execution of License Agreement on Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory [ PDF 82.0 KB ]
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.